Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study

Area of Science:

• Hepatology
• Oncology
• Clinical Research

Background:

• Hepatocellular carcinoma (HCC) is a rare but serious complication of primary biliary cirrhosis (PBC).
• Predictive tools for HCC development in PBC patients are currently limited.
• Identifying risk factors is crucial for early detection and management.

Purpose of the Study:

• To identify candidate risk factors for HCC development in patients with PBC.
• To evaluate the association between biochemical response to ursodeoxycholic acid and HCC risk.
• To establish a robust predictive model for HCC in PBC.

Main Methods:

• A large-scale, international cohort study involving over 15 centers and spanning more than 40 years.
• Utilized Cox proportional hazards assumptions, logistic regression, and Kaplan-Meier estimates for risk factor analysis.
• Included 4565 patients with PBC, with 123 developing HCC.

Main Results:

• HCC incidence was 3.4 cases/1000 patient-years and significantly more common in men.
• Univariate analysis identified male sex, elevated AST, advanced disease, thrombocytopenia, and hepatic decompensation as risk factors.
• Crucially, 12-month biochemical non-response (Paris-I criteria) was the most significant predictor of future HCC risk (adjusted HR 3.44, p<0.0001).

Conclusions:

• Biochemical non-response after 12 months of ursodeoxycholic acid treatment is a significant independent predictor of HCC development in PBC.
• This risk stratification is valuable for clinical management and the development of novel therapeutic strategies.
• The findings are based on a robust, internationally representative cohort study.